NCT00002429已完成3 期
Evaluation of HIV RNA Suppression Produced by a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine (ddI EC) Administered Once Daily Compared to a Reference Combination Regimen
Bristol-Myers Squibb43 个研究点 分布在 2 个国家目标入组 500 人开始时间: 1999年7月最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 500
- 试验地点
- 43
研究概览
简要总结
This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach before dissolving. The purpose of this study is to compare the effectiveness of an anti-HIV drug combination that includes ddI EC versus another anti-HIV drug combination.
详细描述
Patients are randomized to 1 of 2 groups for 48 weeks of open-label treatment. Group 1 receives ddI EC plus d4T plus NFV. Group 2 receives Combivir plus NFV. Antiviral activity is determined by the proportion of patients with HIV RNA levels of less than 400 copies/ml at Week 48.
研究设计
- 研究类型
- Interventional
- 干预模型
- Parallel
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (43)
Loading locations...
相似试验
已完成
3 期
Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)HIV InfectionsNCT00002224Bristol-Myers Squibb120
已完成
3 期
A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2',3'-DideoxyinosineAIDS-Related ComplexAcquired Immunodeficiency SyndromeNCT00001267National Cancer Institute (NCI)42
已完成
不适用
Suppression of HIV 1 RNA in People Living With HIVHIVNCT02363387Johns Hopkins University102
撤回
4 期
A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear CellsAcquired Immune Deficiency SyndromeHIV InfectionsNCT01173510Community Research Initiative of New England
已完成
2 期
Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected PatientsHIV InfectionsNCT00038220Abbott40